UK businesses are invited to join the Department for International Trade Oncology mission to China. As the second largest healthcare market in the world the opportunity for UK businesses is huge, with its competitive advantage and innovative high-tech solutions.
Cancer is a growing global health challenge and China represents more than 20% of newly diagnosed cancers worldwide and approximately 27% of global cancer deaths. Through the Healthy China 2030 policy and other legislative vehicles, the Chinese government has made it a priority to tackle cancer. State and private healthcare spending is growing accordingly. While the state insurance schemes remain the dominant source of healthcare funding, China’s rapidly growing wealth levels and middle class population is driving growth in out-of-pocket spending and private health insurance cover also.
- 2nd largest healthcare market in the world
- £7bn spend p.a. on Cancer Drugs (17% yearly growth)
- £6.8bn spend p.a. on In Vitro Diagnostics (IVD)
- £5.6bn spend p.a. on imaging
The opportunity for the UK therefore is huge, with its competitive advantage and an innovative high-tech oncology sector.
TARGET UK ORGANISATIONS (public and private sector):
UK-based organisations with an oncology proposition at any part of the patient pathway: hospital design, clinical services, education & training, med-tech, medical devices, diagnostics, strategic planning/consultancy, digital oncology, pharmaceuticals.
View the ‘Opportunities for UK Life Sciences companies in China video‘ for a better understanding.
Full details, including how to register are found here .